Nash’s NASH NP-160 shows repeated positive results in second pre-clinical study

Image: Nash Pharmaceuticals has announced 84% reduction of fibrosis by additional lead compound in second pre-clinical study for non-alcoholic fatty liver disease. Photo: courtesy of dream designs / FreeDigitalPhotos.net.